Lisa A. Carey, MD

Lisa A. Carey MD, ScM, FASCO, discusses the varying approaches to response-guided therapy in HER2-positive breast cancer.

Lisa A. Carey MD, ScM, FASCO, discusses the use of response-guided therapy in HER2-positive breast cancer.

Lisa A. Carey, MD, FASCO, discusses the clinical implications of the phase 3 FeDeriCa trial in HER2-positive breast cancer.

Lisa A. Carey, MD, professor, UNC Lineberger Comprehensive Cancer Center, discusses findings from the CALGB 40502/NCCTG N063H trial in triple-negative breast cancer.

Lisa A. Carey, MD, professor, UNC Lineberger Comprehensive Cancer Center, discusses the CALGB 40502/NCCTG N063H trial in patients with triple-negative breast cancer (TNBC).

Lisa A. Carey, MD, professor, UNC Lineberger Comprehensive Cancer Center, discusses de-escalating treatments for patients with triple-negative breast cancer (TNBC).

Lisa A. Carey, MD, professor, UNC Lineberger Comprehensive Cancer Center, discusses tailoring treatment for patients with triple-negative breast cancer (TNBC).

Lisa A. Carey, MD, professor of medicine, Breast Cancer Research, University of North Carolina, medical director, UNC Breast Center, chief of Hematology/Oncology, physician-in-chief, UNC North Carolina Cancer Hospital, discusses treatment options and challenges in triple-negative breast cancer.

Lisa A. Carey, MD, the Division Chief of Hematology and Oncology at the University of North Carolina and the Physician-in-Chief at North Carolina Cancer Hospital, discusses triple-negative breast cancer (TNBC) and the importance of understanding how it differs from other types of breast cancer.

Lisa A. Carey, MD, Professor of Medicine, University of North Carolina at Chapel Hill, discusses the present and future state of clinical trial design.

Lisa A. Carey, MD, Professor of Medicine, University of North Carolina at Chapel Hill, discusses the use of everolimus in the metastatic and adjuvant settings of breast cancer.

Lisa A. Carey, MD, Professor of Medicine, University of North Carolina at Chapel Hill, discusses the field of psycho-oncology.

Dr. Lisa Carey Discusses the Need for Targeted Therapy in Triple Negative Breast Cancer (TNBC)